Form 4: Alzamend Director Sells Shares After Preferred Conversion
Insider Trading Report
Alzamend Neuro Director Milton C. Ault III reported the conversion of preferred stock into common shares and subsequent sales of common stock totaling over 123,000 shares.
Summary
- Milton C. Ault III, a Director of Alzamend Neuro, Inc. (ALZN), reported transactions involving the company's common stock and derivative securities.
- On October 1, 2025, 100,000 shares of common stock were acquired indirectly by Ault Lending, LLC, upon the conversion of Series B convertible preferred stock at a price of $2.32 per share.
- Following the acquisition, Ault Lending, LLC, beneficially owned 131,626 shares of common stock.
- On October 1, 2025, 36,777 shares of common stock were disposed of indirectly by Ault Lending, LLC, in open market transactions at a volume-weighted average sale price of $2.3487 per share.
- On October 2, 2025, an additional 20,686 shares of common stock were disposed of indirectly by Ault Lending, LLC, at a volume-weighted average sale price of $2.394 per share.
- On October 3, 2025, 65,903 shares of common stock were disposed of indirectly by Ault Lending, LLC, at a volume-weighted average sale price of $2.4413 per share.
- After all reported transactions, Ault Lending, LLC, beneficially owned 8,260 shares of common stock.
- Mr. Ault also directly owned 1,843 shares of common stock and indirectly owned 11,068 shares through Ault Life Sciences, Inc., and 61 shares through Ault Life Sciences Fund, LLC.
- Derivative securities held indirectly by Ault Lending, LLC, include Common Stock Purchase Warrants with various exercise and expiration dates, and a remaining balance of Series B Convertible Preferred Stock.
Sentiment
Score: 3
Explanation: The sentiment is negative due to the significant net selling of common stock by a director. While the conversion of preferred stock is a neutral event, the subsequent and substantial disposition of common shares by an insider typically signals a bearish outlook from that individual.
Negatives
- A significant net disposition of 123,366 common shares by a director (Milton C. Ault III) through Ault Lending, LLC, over three days, which can be interpreted as a lack of confidence in the near-term stock performance.
Risks
- Insider selling can signal potential concerns about the company's future prospects or valuation, potentially leading to negative market sentiment and downward pressure on the stock price.
Future Outlook
The filing does not provide any forward-looking statements or guidance regarding the company's future performance or strategic direction; it solely reports insider transactions.
Industry Context
This Form 4 filing reports insider trading activity, which is a routine disclosure for publicly traded companies. It does not provide broader industry context or trends.
Related Party Transactions
- Milton C. Ault III's transactions were conducted indirectly through Ault Lending, LLC, a wholly-owned subsidiary of Hyperscale Data, Inc. (HSD), where Mr. Ault is Executive Chairman. He is deemed to have voting and investment power over securities held by Ault Lending, LLC.
- Mr. Ault also holds securities indirectly through Ault Life Sciences, Inc. and Ault Life Sciences Fund, LLC, over which he has sole voting and investment power.
Stakeholder Impact
- Shareholders may interpret the director's significant selling activity as a negative signal regarding the company's future performance or valuation, potentially impacting investor confidence and stock price.
- Potential investors might view this insider selling as a cautionary sign, influencing their investment decisions.
Key Dates
| Date | Description |
|---|---|
| 2024-01-31 | Expiration date for Series B Convertible Preferred Stock (Note: Filing states 'no expiration date' for Series B Preferred, but lists this date for the converted shares). |
| 2024-08-01 | Date exercisable for certain Common Stock Purchase Warrants. |
| 2024-09-27 | Date exercisable for certain Common Stock Purchase Warrants. |
| 2024-10-30 | Date exercisable for certain Common Stock Purchase Warrants. |
| 2025-10-01 | Acquisition of 100,000 common shares via Series B Preferred conversion and disposition of 36,777 common shares. |
| 2025-10-02 | Disposition of 20,686 common shares. |
| 2025-10-03 | Disposition of 65,903 common shares and filing date of the Form 4. |
| 2029-08-01 | Expiration date for certain Common Stock Purchase Warrants. |
| 2029-09-27 | Expiration date for certain Common Stock Purchase Warrants. |
| 2029-10-30 | Expiration date for certain Common Stock Purchase Warrants. |
Recommendation
sellThe significant net disposition of common stock by a director, Milton C. Ault III, following a preferred stock conversion, typically signals a lack of confidence in the company's near-term prospects or that the stock is currently overvalued. Seasoned investors often view substantial insider selling as a bearish indicator, suggesting it might be prudent to sell or reduce exposure to the stock.
Keywords
Alzamend Neuro, ALZN, Milton C. Ault III, Insider Trading, Form 4, Stock Sale, Preferred Stock Conversion, Director Transactions, Equity Sales, Ault Lending LLC
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.